| Oct 28 |
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
|
| Oct 19 |
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years
|
| Oct 16 |
FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment
|
| Oct 15 |
UroGen Pharma announces FDA acceptance of new drug application for UGN-102
|
| Oct 15 |
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
|
| Oct 14 |
UroGen started at buy by EF Hutton, RTGel technology cited
|
| Oct 9 |
UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
|
| Oct 9 |
UroGen Pharma names Chris Degnan as CFO
|
| Oct 9 |
UroGen Appoints Chris Degnan as Chief Financial Officer
|
| Oct 3 |
UroGen begins subject dosing in Phase III bladder cancer drug trial
|
